142 related articles for article (PubMed ID: 29401241)
1. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701).
Kodaira T; Kagami Y; Shibata T; Shikama N; Nishimura Y; Ishikura S; Nakamura K; Saito Y; Matsumoto Y; Teshima T; Ito Y; Akimoto T; Nakata K; Toshiyasu T; Nakagawa K; Nagata Y; Nishimura T; Uno T; Kataoka M; Yorozu A; Hiraoka M;
Ann Oncol; 2018 Apr; 29(4):992-997. PubMed ID: 29401241
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Epithelial Cell Adhesion Molecules in T1-2N0M0 Glottic Cancer.
Murakami N; Mori T; Machida R; Kodaira T; Ito Y; Shikama N; Konishi K; Matsumoto Y; Murakami Y; Nakamura N; Yamashita H; Yorozu A; Yoshimura M; Inoue K; Nozaki M; Ishikura S; Itami J; Nishimura Y; Kagami Y
Laryngoscope; 2021 Jul; 131(7):1522-1527. PubMed ID: 33369763
[TBL] [Abstract][Full Text] [Related]
3. Accelerated fractionation versus conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study: Japan Clinical Oncology Group study (JCOG 0701).
Nakamura K; Kodaira T; Shikama N; Kagami Y; Ishikura S; Shibata T; Hiraoka M
Jpn J Clin Oncol; 2008 May; 38(5):387-9. PubMed ID: 18390558
[TBL] [Abstract][Full Text] [Related]
4. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
Sakata K; Oouchi A; Nagakura H; Akiba H; Tamakawa M; Koito K; Hareyama M; Asakura K; Satoh M; Ohtani S
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):81-8. PubMed ID: 10758308
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
Sakata K; Someya M; Hori M; Nakata K; Takagi M; Hareyama M
Strahlenther Onkol; 2008 Jul; 184(7):364-9. PubMed ID: 19016035
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3).
Kodaira T; Kagami Y; Machida R; Shikama N; Sekino Y; Ito Y; Ishikura S; Saito Y; Matsumoto Y; Konishi K; Murakami N; Akimoto T; Fukushima Y; Toshiyasu T; Katano A; Nagata Y; Ogawa H; Uno T; Hamamoto Y; Nishimura Y; Mizowaki T
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1118-1124. PubMed ID: 37414261
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
10. Accelerated radiotherapy for T1 to T2 glottic cancer.
Motegi A; Kawashima M; Arahira S; Zenda S; Toshima M; Onozawa M; Hayashi R; Akimoto T
Head Neck; 2015 Apr; 37(4):579-84. PubMed ID: 24677592
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
12. Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy.
Oie Y; Itoh Y; Kawamura M; Takase Y; Murao T; Ishihara S; Nomoto Y; Hirasawa N; Asano A; Yamakawa K; Ito J; Kinoshita F; Naganawa S
Nagoya J Med Sci; 2021 Nov; 83(4):811-825. PubMed ID: 34916724
[TBL] [Abstract][Full Text] [Related]
13. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
[TBL] [Abstract][Full Text] [Related]
14. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).
Trotti A; Zhang Q; Bentzen SM; Emami B; Hammond ME; Jones CU; Morrison WH; Sagar SM; Ridge JA; Fu KK; Ang KK
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):958-963. PubMed ID: 25035199
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.
Salas-Salas BG; Domínguez-Nuez DJ; Cabrera R; Ferrera-Alayón L; Lloret M; Lara PC
Clin Transl Oncol; 2020 Jan; 22(1):151-157. PubMed ID: 31152306
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.
Nishimura Y; Nagata Y; Okajima K; Mitsumori M; Hiraoka M; Masunaga S; Ono K; Shoji K; Kojima H
Radiother Oncol; 1996 Sep; 40(3):225-32. PubMed ID: 8940749
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in elderly patients with T1 glottic cancer treated with radiotherapy.
Mucha-Małecka A; Małecki K; Amrogowicz N; Biesaga B; Modrzejewski M
Sci Rep; 2021 Sep; 11(1):17717. PubMed ID: 34489495
[TBL] [Abstract][Full Text] [Related]
19. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.
Ricciardelli EJ; Weymuller EA; Koh WJ; Austin-Seymour M; DeSautel MG; Laramore GE
Arch Otolaryngol Head Neck Surg; 1994 Jul; 120(7):737-42. PubMed ID: 8018326
[TBL] [Abstract][Full Text] [Related]
20. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
